US FDA confirms biosimilars regulation meeting dates
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has formally announced that it will hold a two-day public hearing to gather feedback from stakeholders on specific issues and challenges associated with the implementation of the Biologics Price Competition and Innovation Act of 20091-3.